Mirum charts positive course for hepatitis delta drug on first Phase III win

Phase 3positivebrelovitugPositive

AI Analysis

Summary

Mirum reported positive Phase III trial results for brelovitug in chronic hepatitis delta virus and plans to submit a BLA in H1 2027 pending success in its second Phase III trial.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

First Phase III trial for brelovitug in chronic HDV achieved positive results

Importance:8/10

Sentiment:

0.70

Phase IIIBLA submissionhepatitis deltabrelovitugpositive trial data

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 29, 2026 11:08 AM

Read Original